Modification of Apremilast from Pills to Aerosol a Future Concept

Paul Zarogoulidis, Christoforos Kosmidis, Nikolaos Kougkas, Aimilios Lallas, Dimitris Petridis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Lutz Freitag and Chrisanthi Sardeli
Additional contact information
Paul Zarogoulidis: Pulmonary Department, General Clinic, Euromedica Private Hospital, 546 45 Thessaloniki, Greece
Christoforos Kosmidis: 3rd Surgery Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 546 21 Thessaloniki, Greece
Nikolaos Kougkas: Rheumatology Department, IPPOKRATEIO University General Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
Aimilios Lallas: 1st Dermatology Department, Aristotle University of Thessaloniki, 540 06 Thessaloniki, Greece
Dimitris Petridis: Department of Food Science and Technology, International Hellenic University, 507 01 Thessaloniki, Greece
Wolfgang Hohenforst-Schmidt: Sana Clinic Group Franken, Department of Cardiology, Pulmonology, Intensive Care, Nephrology, Hof Clinics, University of Erlangen, 91054 Hof, Germany
Haidong Huang: Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Naval Medical University (Changhai Hospital, Second Military Medical University), Shanghai 200433, China
Lutz Freitag: Department of Pulmonology, University Hospital Zurich, 8091 Zurich, Switzerland
Chrisanthi Sardeli: Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 546 45 Thessaloniki, Greece

IJERPH, 2021, vol. 18, issue 21, 1-9

Abstract: Background: Inhaled drugs have been available in the market for several years and for several diseases. Drugs for chronic obstructive pulmonary disease, cystic fibrosis, and diabetes have been used for several years. In the field of drug modification, these drugs range from tablets to aerosol. Methods: Milling as used to break down the tablets to powder and nebulisers are used to produce aerosol droplets. A mastersizer was used to measure the mass median aerodynamic diameter of the aerosol droplets. Results: Apremilast produced mmad diameters (2.43 ?m) without any statistical difference between the different jet-nebulizers. The residual cup B contributed to greater mmad diameters as the 95% interval of mean values, based on those the ANOVA mean square clearly indicated, followed by cups C and F. The previous interval plot is much better clarified when the interaction means between drug and residual cap are plotted. The residual cups B, C and F produce mmad between (2.0–3.2). Conclusion: In the current research study we demonstrated our methodology to create apremilast powder and produce apremilast aerosol droplets with different nebulisers and residual cups.

Keywords: nebulisers; jet-nebulisers; ultrasound nebulisers; apremilast; psoriasis; mastersizer (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/21/11590/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/21/11590/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:21:p:11590-:d:672039

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().